目的 探討阿托伐他汀聯(lián)合曲美他嗪對(duì)心血瘀阻證患者的療效及對(duì)血清超氧化物歧化酶（SOD）、丙二醛（MDA）的影響。方法 選取2012年1月-2017年6月西安北車(chē)醫(yī)院收治的68例心血瘀阻證患者，按治療方法分成對(duì)照組34例、觀(guān)察組34例。對(duì)照組通過(guò)口服曲美他嗪片治療，每次20 mg，每天3次；觀(guān)察組在此基礎(chǔ)上聯(lián)合阿托伐他汀治療，20 mg/次，1次/d。兩組的療程均為8周。比較兩組治療后心絞痛的改善情況，治療前后心絞痛發(fā)作次數(shù)、每次持續(xù)時(shí)間，比較兩組治療前后血清SOD活力、MDA含量的變化，比較治療期間不良反應(yīng)的發(fā)生情況。結(jié)果 觀(guān)察組臨床療效的總有效率是94.12%（32/34），顯著高于對(duì)照組的82.35%（28/34），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療后心絞痛發(fā)作次數(shù)及每次持續(xù)時(shí)間均較治療前顯著下降（P<0.05），且觀(guān)察組明顯低于對(duì)照組（P<0.05）。兩組治療后血清SOD活力顯著升高（P<0.05），MDA含量顯著降低（P<0.05），且觀(guān)察組比對(duì)照組更明顯（P<0.05）。治療期間，兩組均未發(fā)生嚴(yán)重的不良反應(yīng)。結(jié)論 阿托伐他汀聯(lián)合曲美他嗪治療心血瘀阻證療效確切，安全可靠，可能與有效提高血清SOD活力、降低血清MDA含量有關(guān)。

Objective To explore the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of patients with coronary heart disease angina pectoris stasis syndrome, and its effects of serum SOD and MDA. Methods Selected 68 patients with coronary heart disease angina pectoris stasis syndrome in our hospital from January 2014 to June 2017. All patients were divided into control group and observation group by treatment methods, each of group of 34 cases. The control group was treated with trimetazidine on the basis of routine treatment. The observation group was treated with atorvastatin on basis of control group. The clinical efficacy, times of angina pectoris episodes, duration of angina pectoris episodes, serum SOD activity and MDA content, and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was 94.12% (32/34), which was significantly higher than that in the control group (82.35%, 28/34) (P<0.05). The times of angina pectoris episodes and duration of angina pectoris episodes of two groups were significantly lower than those before treatment (P<0.05), and the observation group was significantly lower than the control group (P<0.05). After treatment, serum SOD activity was significantly increased (P<0.05), MDA content was significantly lower (P<0.05), and the observation group was more obvious than the control group (P<0.05). During treatment, no serious adverse reactions occurred in both groups. Conclusions Atorvastatin combined with trimetazidine treatment of coronary heart disease angina pectoris stasis syndrome efficacy of the exact, safe and reliable, may be associated with an effective increase in serum SOD activity, lower serum MDA levels.